InvestAcure is an online investment platform that allows you to automatically round out your day-to-day transactions and invest the spare change in innovative companies spearheading the search for an Alzheimer's cure . Here’s how it works:
Setup your investment account online. Connect the credit cards you use most and spend normally.
We round up all your purchases to the nearest dollar and guided by our panel of leading scientists, invest the spare change in companies working to find a cure for Alzheimer’s.
Your spare change is an investment, not a donation! You own stock in the companies spearheading cutting edge research.
By joining InvestAcure, you’re also instantly connected to a community of people who share your passion in curing Alzheimer’s and have access to the latest research.
1. Our mission is to find a cure for Alzheimer's, so our investment decisions are guided by science, not profit!
2. Unlike a charity, however, your money is not given away; you own stock in each company you invest in. If a cure is found by one of the companies that you helped fund, it's only fair that you're not only entitled to feel a sense of pride in doing your part to save countless lives, but also to share in the financial benefits as well.
Your spare change investment decisions are guided by our panel of world class Alzheimer's scientists and will purchase shares in publicly traded companies actively searching for a cure.
Editor & Chief of the Alzheimer's Journal of Disease, Dean at the University of Texas-San Antonio, neuroscientist distinguished as one of the top Alzheimer’s disease researchers, one of the top100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in free radical research.
Headed Alzheimer's research at Johnson & Johnson, developing one of only 5 approved Alzheimer’s drugs. Currently, serves as the CSO of In Silico, a company providing disease modeling services in CNS Drug Discovery & Development and on the faculty of the Perelman School of Medicine and the Drexel University Dept. of Pharmacology.
Professor of Pharmaceutical Sciences at USciences. He serves on many national panels including NIH and Alzheimer’s Association grant review committees. His efforts have resulted in more than 50 publications, 5 patents, and more than 100 presentations at national and international conferences.